hotspot -WSS

hotspot

author：fashion 2025-09-30 00:40:15 - browse：4

A sign of The Cigna Group in front of trees with orange and green leaves — insurance overage from STAT — Joe Buglewicz/Bloomberg

Cigna and Humana are in discussions to merge, a potential move that would create a health insurance and prescription drug benefits titan with approximately $300 billion of annual revenue.

A proposed transaction would almost certainly prompt a close review from antitrust enforcers at the Department of Justice and the Federal Trade Commission. A merged Cigna-Humana would further consolidate the market for pharmacy benefit managers. PBMs are companies that serve as the controversial middlemen of drug pricing negotiations, and of the four largest, two are owned by Cigna and Humana.

The Wall Street Journal first reported the talks between Cigna and Humana on Wednesday, citing sources close to the situation. Wendell Potter, a health insurance whistleblower who used to work at Cigna, also wrote about merger discussions between Cigna and Humana on his blog Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： 2023 Nobel Prize in Medicine goes to Karikó and Weissman

Wikipedia

WSS

CDC picks Alphabet's Verily for wasterwater surveillance contract

IVG is promising — but it won’t replace IVF quite yet

Asbestos ban is immediate, but health effects will linger for decades

CRISPR technology availability, affordability needs to be expanded

Bring on the sabbaticals for nurses

What will Novo Nordisk's VC do with its influx of cash?

explore

hotspot

explore

Apple is now the first public company to be valued at $3 trillion

With Wegovy coverage, Medicare patients may face high costs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The stability of $0 premiums in Medicare Advantage

Drug repurposing or repositioning? The language matters

Pfizer, Moderna say biotech, pharma drug development is a sprint

Anesthesiologist group: stop taking Ozempic before surgery

6 solutions to address cancer drug shortages and others

How one medical school became remarkably diverse

Flu, Covid vaccination rates decline, new survey data show

focus

'Patient friction coefficient' can gauge a clinical trial's patient burden

What Kate Middleton's cancer revelation might teach the world

'Patient friction coefficient' can gauge a clinical trial's patient burden

Mirador, a new biotech startup, launches with $400 million

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

The United States is paying nearly triple for new Covid vaccines

hotspot

Wikipedia

focus

leisure time